Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas

By afschroeder • June 12, 2025

Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim SB, Wong DJ, Powell SF, Khilnani A, Jemielita T, Zhao Q, Zhao R, Ingham M. Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Jun 11. doi: 10.1158/1078-0432.CCR-24-3630. Epub ahead of print. PMID: 40499147.

Tags: Hematology/Oncology, Publications

Understanding Barriers to Colon Cancer Screening Among Individuals Experiencing Housing Insecurity in Los Angeles

Burra A, Gonzales N, Jiang J, Zhang S, Obasi M, Eeraveni A, Garcia Jimenez M, Goldgar S. Understanding Barriers to Colon Cancer Screening Among Individuals[...]

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.[...]

Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease

Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI. Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion[...]